[1]WANG W,HE S,JI J,et al.The prognostic significance of FOXQ1 oncogene overexpression in human hepatocellular carcinoma[J].Pathol Res Pract,2013,209(6):353-358.
|
[2]KANEDA H,ARAO T,TANAKA K,et al.FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth[J].Cancer Res,2010,70(5):2053-2063.
|
[3]ZHANG H,MENG F,LIU G,et al.Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis[J].Cancer Res,2011,71(4):1292-1301.
|
[4]XIA L,HUANG W,TIAN D,et al.Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV 1 expression[J].Hepatology,2014,59(3):958-973.
|
[5]FENG J,ZHANG X,ZHU H,et al.Fox Q1 overexpression influences poor prognosis in non-small cell lung cancer,associates with the phenomenon of EMT[J].PLoS One,2012,7(6):e39937.
|
[6]PENG X,LUO Z,KANG Q,et al.FOXQ1 mediates the crosstalk between TGF-βand Wnt signaling pathways in the progression of colorectal cancer[J].Cancer Biol Ther,2015,16(7):1099-1109.
|
[7]FENG J,XU L,NI S,et al.Involvement of Fox Q1 in NSCLC through regulating EMT and increasing chemosensitivity[J].Oncotarget,2014,5(20):9689-9702.
|
[8]YAMAKADO K,HIROTA S.Sub-classification of intermediate-stage(Barcelona Clinic Liver Cancer stage-B)hepatocellular carcinomas[J].World J Gastroenterol,2015,21(37):10604-10608.
|
[9]ZHOU YL,SHAO BF,SHI DH,et al.Association between PET-CT imaging and tumor pathological classification in hepatocellular carcinoma[J].J Nantong Univ:Med Sci,2012,32(5):391-393.(in Chinese)周益龙,邵冰峰,施冬辉,等.肝细胞肝癌PET-CT显像与肿瘤病理分级的相关性研究[J].南通大学学报:医学版,2012,32(5):391-393.
|
[10]ZHOU YL SHAO BF,XU AB,et al.Value of indocyanine green retention rate at 15 minutes in surgical treatment of resectable liver cancer after multiple transarterial chemoembolization treatments[J].J Nantong Univ:Med Sci,2012,35(4):295-297.(in Chinese)周益龙,邵冰峰,徐爱兵,等.ICGR15在多次肝动脉栓塞化疗后的可切除性肝癌外科治疗中的意义[J].南通大学学报:医学版,2012,35(4):295-297.
|
[11]CHENG HY.Interventional treatment for hepatocellular carcinoma:a review of current status and perspectives[J].J Clin Hepatol,2016,32(1):3-8.(in Chinese)程红岩.肝癌介入治疗的现状与展望[J].临床肝胆病杂志,2016,32(1):3-8.
|
[12]MA SJ,ZOU SJ,LUO XL,et al.Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J].J Clin Hepatol,2016,32(1):80-83.(in Chinese)马士杰,邹绍静,罗小玲,等.经肝动脉化疗栓塞术治疗肝细胞癌的预后影响因素分析[J].临床肝胆病杂志,2016,32(1):80-83.
|
[13]FENG M,E CY,LI H,et al.Expression of miR-196a in liver cancer cells and its promotion effect on proliferation[J].J Jilin Univ:Med Edit,2015,41(1):120-124.(in Chinese)冯默,鄂长勇,李航,等.miR-196a在肝癌细胞中的表达及其促增殖作用[J].吉林大学学报:医学版,2015,41(1):120-124.
|
[14]QIN J,XU Y,LI X,et al.Effects of lentiviral-mediated Foxp1 and Foxq1 RNAi on the hepatocarcinoma cell[J].Exp Mol Pathol,2014,96(1):1-8.
|